Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity
Thao N.D. Pham, … , David J. Bentrem, Hidayatullah G. Munshi
Thao N.D. Pham, … , David J. Bentrem, Hidayatullah G. Munshi
Published April 5, 2022
Citation Information: JCI Insight. 2022;7(9):e152731. https://doi.org/10.1172/jci.insight.152731.
View: Text | PDF
Research Article Immunology

Inhibition of MNKs promotes macrophage immunosuppressive phenotype to limit CD8+ T cell antitumor immunity

  • Text
  • PDF
Abstract

To elicit effective antitumor responses, CD8+ T cells need to infiltrate tumors and sustain their effector function within the immunosuppressive tumor microenvironment (TME). Here, we evaluate the role of MNK activity in regulating CD8+ T cell infiltration and antitumor activity in pancreatic and thyroid tumors. We first show that human pancreatic and thyroid tumors with increased MNK activity are associated with decreased infiltration by CD8+ T cells. We then show that, while MNK inhibitors increase CD8+ T cells in these tumors, they induce a T cell exhaustion phenotype in the tumor microenvironment. Mechanistically, we show that the exhaustion phenotype is not caused by upregulation of programmed cell death ligand 1 (PD-L1) but is caused by tumor-associated macrophages (TAMs) becoming more immunosuppressive following MNK inhibitor treatment. Reversal of CD8+ T cell exhaustion by an anti–PD-1 antibody or TAM depletion synergizes with MNK inhibitors to control tumor growth and prolong animal survival. Importantly, we show in ex vivo human pancreatic tumor slice cultures that MNK inhibitors increase the expression of markers associated with immunosuppressive TAMs. Together, these findings demonstrate a role of MNKs modulating a protumoral phenotype in macrophages and identify combination regimens involving MNK inhibitors to enhance antitumor immune responses.

Authors

Thao N.D. Pham, Christina Spaulding, Mario A. Shields, Anastasia E. Metropulos, Dhavan N. Shah, Mahmoud G. Khalafalla, Daniel R. Principe, David J. Bentrem, Hidayatullah G. Munshi

×

Figure 4

Antitumor efficacy of combined anti–PD-1 antibody and MNK inhibitors is dependent on CD8+ T cells.

Options: View larger image (or click on image) Download as PowerPoint
Antitumor efficacy of combined anti–PD-1 antibody and MNK inhibitors is ...
Mice with KPC-344 tumors were randomized and treated with CGP57380 (25 mg/kg, daily) or DMSO in combination with an anti–PD-1 antibody (200 μg, twice weekly) or an isotype-matched IgG antibody (200 μg, twice weekly). (A) Tumor size was measured daily, and tumor volume was calculated using the formula V = (W2 × L)/2. (B) At the study endpoint, the tumor-infiltrating CD8+ T cells were isolated and analyzed by flow cytometry for perforin-1 (Prf1) and granzyme B (GzmB). (C and D) Tumors collected at the endpoint were stained by IHC for GzmB (top panel) and were immunofluorescence costained for cytokeratin 8 (CK8) and Ki67 and counterstained with DAPI (bottom panel). Scale bar: 50 μm. The absolute number of GzmB+ cells per 10× section and the number of Ki67+ cells as a percentage of CK8+ cells were quantified by ImageJ and analyzed by GraphPad. Data points in B and D represent individual tumors. (E) In addition to treating with CGP57380 and an anti–PD-1 antibody, KPC-344 tumor-bearing mice were cotreated with a CD8+ T cell–depleting antibody (300 μg, on day –2, day 0, and then twice weekly). The overall survival of KPC-344 tumor-bearing mice was determined as described in Methods. Log-ranked (Mantel-Cox) test for survival analysis was performed by GraphPad. ***P < 0.001. (F) The KPC-344 tumor-bearing mice were treated with CGP57380 and an anti–PD-1 antibody and cotreated with a CD8+ T cell–depleting antibody. Tumor volume was calculated as described above. The efficacy of the anti-CD8 antibody was confirmed by IHC staining for CD8. In B, D, and F, data are shown as the mean ± SEM, and analysis was done using 1-way ANOVA followed by Dunnett’s multiple comparison test. *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts